Facundo Garcia-Bournissen

Facundo Garcia-Bournissen

Auto-generated profile, based on publicly available information

Facundo Garcia-Bournissen

Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry Western University London Ontario Canada

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2011 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
JHJ R Hutson
J R Hutson
FGF Garcia-Bournissen
F Garcia-Bournissen
ADA Davis
A Davis
GKGideon Koren
Gideon Koren

1 October 2011 in Pediatrics
Verified
Journal Article
Closed access
PDF file
YFYaron Finkelstein
Yaron Finkelstein
GSGordon S. Soon
Gordon S. Soon
PAPatrick Acuna
Patrick Acuna
MGMathew George
Mathew George
EPElena Pope
Elena Pope
FGFacundo Garcia-Bournissen
Facundo Garcia-Bournissen
OBJECTIVES: To report clinical course, etiology, management, and long-term outcomes of children suffering from Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). METHODS: We conducted a study of all pediatric patients with SJS or TEN admitted between 2000 and 2007 to the Hospital for Sick Children and Children9s Hospital Boston, and particular attention was paid to clinical manifestations, etiology, mortality, and long-term outcomes. RESULTS: We identified 55 cases of SJS (n = 47), TEN (n = 5), or SJS/TEN overlap syndrome (n = 3). Drugs were identified as the most likely etiologic agent in 29 children (53%); antiepileptic drugs were the most common agents (n = 16), followed by sulfonamide antibiotics (n = 7) and chemotherapy drugs (n = 2). Acute Mycoplasma pneumoniae infection was confirmed in 12 children (22%), and herpes simplex virus was confirmed in 5 children (9%). Treatment regimens differed significantly between participating sites and included systemic antimicrobial agents (67%), systemic corticosteroids (40%), and antiviral drugs (31%). Intravenous immunoglobulin was administered to 21 children (38%), of whom 8 received concomitant systemic corticosteroids. Ten children (18%) had recurrence of SJS up to 7 years after the index episode, and 3 experienced multiple recurrences. Twenty-six children (47%) suffered long-term sequelae that mostly involved the skin and eyes. CONCLUSIONS: Mortality rate in children was lower than that reported in adults, but half of affected children suffered long-term complications. The recurrence rate of SJS was high (1 in 5), which suggests vulnerability and potential genetic predisposition. In the absence of standardized management guidelines for these conditions, treatment regimens differed significantly between participating institutions.

19 September 2018 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Open access
JKJadel Müller Kratz
Jadel Müller Kratz
FBFacundo Garcia Bournissen
Facundo Garcia Bournissen
Colin ForsythColin Forsyth
Colin Forsyth
SSSergio Sosa-Estani
Sergio Sosa-Estani
Chagas disease (CD) is one of the most neglected public health problems in the Americas, where <1% of the estimated 6 million people with the infection have been diagnosed and treated. The goal of treatment is to eliminate the parasite, decrease the probability of cardiomyopathy and other complications during the chronic stage of infection, and interrupt the cycle of disease transmission by preventing congenital infection. Currently, only benznidazole (BZN) and nifurtimox are recognized by the World Health Organization as effective drugs for treatment of CD. In this paper, we provide an overview of the clinical pharmacology of BZN. Areas covered: This review covers the historical background, chemistry, mechanism of action, pharmacokinetics, preclinical research, resistance, clinical research, toxicology, adverse effects, and current regulatory status of BZN. Expert commentary: Ongoing investigations aim to optimize BZN therapy by adjusting the current standard regimen or by combining BZN with new chemical entities. These studies are assessing alternatives that improve safety while maintaining or increasing the efficacy of BZN. Timely diagnosis and antitrypanosomal treatment are critical components of programs to eliminate CD as a public health problem, and can dramatically reduce the heavy burden of morbidity and mortality caused by the disease.

1 January 2011 in Pediatrics
Verified
Journal Article
Closed access
PDF file
JAJaime ALTCHEH
Jaime ALTCHEH
GMGuillermo Moscatelli
Guillermo Moscatelli
SMSamanta Moroni
Samanta Moroni
FGFacundo Garcia-Bournissen
Facundo Garcia-Bournissen
HFHector Freilij
Hector Freilij
BACKGROUND: Chagas disease is caused by infection with Trypanosoma cruzi. In adults, treatment with benznidazole is associated with a high incidence of adverse drug reactions (ADRs). However, in infants and children, treatment with benznidazole seems associated with a lower incidence and decreased severity of ADRs, but these effects have not been clearly characterized. OBJECTIVE: We aimed to describe ADRs observed in infants and children treated with benznidazole. PATIENTS AND METHODS: We conducted a prospective cohort study of infants and children in Argentina with Chagas disease treated with benznidazole. RESULTS: A total of 107 infants and children diagnosed with asymptomatic Chagas disease (mean age: 6.9 years) were enrolled in the study. Sixty-two events (in 44 children) were considered benznidazole related. Mean ADR duration was 8.2 days. ADRs were mild (80.6%), moderate (16%), or severe (3.2%). Most (77.3%) ADRs were in children older than 7 years. Skin was the organ with the highest incidence of ADRs (21%), followed by the central nervous system (9%) and the gastrointestinal tract (8.5%). Also, the ADR rate was lower in infants and toddlers compared with older children (18% vs 53%) (P < .001). CONCLUSIONS: Treatment with benznidazole was well tolerated in children. Most ADRs were mild and did not require treatment suspension. A strong association was observed between ADR incidence and patient age, and most ADRs occurred in children older than 7 years. We believe that anxiety over potential severe ADRs in children with Chagas disease is not justified and should not be an obstacle to using benznidazole.

1 September 2009 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
NENeda Ebrahimi
Neda Ebrahimi
CMCaroline Maltepe
Caroline Maltepe
FBFacundo Garcia Bournissen
Facundo Garcia Bournissen
GKGideon Koren
Gideon Koren

15 June 2009 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
TTToshihiro Tanaka
Toshihiro Tanaka
KNKen Nakajima
Ken Nakajima
AMAtsuko Murashima
Atsuko Murashima
FGFacundo Garcia-Bournissen
Facundo Garcia-Bournissen
GKGideon Koren
Gideon Koren
SIShinya Ito
Shinya Ito
A new strain of influenza A virus (novel influenza A H1N1) that originated in swine has rapidly spread from the initial outbreak in Mexico and the southern United States to Canada and many countries in Europe and Asia. Consequently, the World Health Organization raised the level of alert for an